Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
280
-
Total 13F shares, excl. options
-
83.3M
-
Shares change
-
-341K
-
Total reported value, excl. options
-
$5.27B
-
Value change
-
+$2.78M
-
Put/Call ratio
-
0.67
-
Number of buys
-
161
-
Number of sells
-
-111
-
Price
-
$63.32
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2023
338 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q2 2023.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 280 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 83.3M shares
of 108M outstanding shares and own 77.29% of the company stock.
Largest 10 shareholders include FMR LLC (11.2M shares), VANGUARD GROUP INC (8.5M shares), BlackRock Inc. (7.59M shares), WASATCH ADVISORS LP (3.49M shares), Bellevue Group AG (3.2M shares), STATE STREET CORP (2.11M shares), ALLIANCEBERNSTEIN L.P. (2.04M shares), JPMORGAN CHASE & CO (1.98M shares), Invesco Ltd. (1.97M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.84M shares).
This table shows the top 280 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.